Abstract: Expression vectors for expression of a protein or polypeptide of interest as a fusion product composed of the protein or polypeptide of interest fused at one terminus to a solubility enhancing peptide extension are provided. Sequences encoding the peptide extensions are provided. The invention further comprises antibodies which bind specifically to one or more of the solubility enhancing peptide extensions.
Type:
Grant
Filed:
January 8, 2010
Date of Patent:
September 17, 2013
Assignee:
Brookhaven Science Associates, LLC
Inventors:
Paul I. Freimuth, Yian-Biao Zhang, Jason Howitt
Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening.
Type:
Grant
Filed:
September 9, 2011
Date of Patent:
September 17, 2013
Assignees:
The United States of America as represented by the Secretary of the Department of Health and Human Services, Research Foundation for Mental Hygiene, Inc., The Progeria Research Foundation, Inc.
Inventors:
B. Maria H. Eriksson, Francis S. Collins, Leslie B. Gordon, W. Ted Brown
Abstract: A perfect palindrome operator sequence-based protein expression system is provided. The expression system comprises a promoter; and a perfect palindrome operator sequence, wherein the promoter is not T7. The expression system is preferably employed for the production of recombinant proteins by fermentation.
Abstract: The present invention relates to animal protein free cell culture media comprising a combination of non-animal derived peptides derived from soy hydrolysate and yeast hydrolysate. The invention also provides an animal protein free culture process, wherein cells are cultivated, propagated and passaged without animal-derived components. This process is useful for cultivating cells, such as recombinant cells or cells infected with a virus, and for production biological products by cell culture processes under conditions devoid of animal protein components.
Type:
Grant
Filed:
May 6, 2011
Date of Patent:
September 3, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Manfred Reiter, Wolfgang Mundt, Leopold Grillberger, Barbara Kraus
Abstract: An object is to provide a means of highly producing an oxalate decarboxylase originating in a microorganism. A recombinant expression plasmid vector, which contains an ?-amylase promoter belonging to the genus Bacillus and an oxalate decarboxylase gene originating in a microorganism that is provided under the control of the promoter, is constructed. A host bacterium is transformed with this vector to prepare an oxalate decarboxylase producing bacterium. A recombinant oxalate decarboxylase is produced by culturing the producing bacterium and then recovering the oxalate decarboxylase thus produced.
Abstract: Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
August 20, 2013
Assignee:
University of Central Florida Research Foundation, Inc.
Abstract: Methods and compositions for cloning a donor DNA molecule into an acceptor vector at a predetermined location are described. The methods are based on homologous recombination mediated by in vitro treatment of the donor DNA and the acceptor vector with an enzyme cocktail containing an exonuclease and a single-stranded DNA binding protein.
Abstract: The present invention relates to methods for producing a polypeptide, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the polypeptide, wherein the fungal host cell comprises a nucleic acid construct comprising a first nucleotide sequence encoding a signal peptide operably linked to a second nucleotide sequence encoding the polypeptide, wherein the first nucleotide sequence is foreign to the second nucleotide sequence and the 3? end of the first nucleotide sequence is immediately upstream of the initiator codon of the second nucleotide sequence. The present invention also relates to the isolated signal peptide sequences and to constructs, vectors, and fungal host cells comprising the signal peptide sequences operably linked to nucleotide sequences encoding polypeptides.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
July 30, 2013
Assignee:
Novozymes, Inc.
Inventors:
Suchindra Maiyuran, Ana Fidantsef, Howard Brody
Abstract: Disclosed herein are methods and systems for expressing a polypeptide in a Rhodospirillum species. The methods include introducing an expression vector having a nucleic acid sequence encoding the polypeptide operably linked to a puc promoter into the Rhodospirillum bacterium and growing the Rhodospirillum bacterium under conditions that allow expression of the polypeptide. Vectors for expressing a membrane polypeptide in a Rhodospirillum species are disclosed. The vectors include a puc promoter and a nucleic acid encoding a membrane polypeptide.
Abstract: The present invention generally relates to methods and compositions for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences.
Type:
Grant
Filed:
May 20, 2011
Date of Patent:
July 2, 2013
Assignee:
Xoma Technology Ltd.
Inventors:
Jeff Gray, Joe Buechler, Uday Kumar Veeramallu
Abstract: The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins.
Type:
Grant
Filed:
May 29, 2012
Date of Patent:
June 25, 2013
Assignee:
Yale University
Inventors:
Jennifer A. Doudna, Louise J. Lucast, Robert T. Batey
Abstract: The present invention is related to a method for the selection of recombinant clones having integrated a gene of interest and a nucleotide sequence encoding a functional antidote protein to a toxic molecule, wherein said recombinant clones are the ones which survive following their integration into a host cell comprising in its genome a nucleotide sequence encoding said toxic molecule. The present invention is also related to a nucleic acid construct, a vector comprising said nucleic acid construct, a host cell and a cloning and/or sequencing kit for performing said method.
Type:
Grant
Filed:
February 22, 2002
Date of Patent:
June 25, 2013
Assignee:
Universite Libre de Bruxelles
Inventors:
Philippe Gabant, Laurence Van Melderen, Cédric Yves Szpirer
Abstract: The subject invention lies in the field of microorganism mutation and selection of the mutants. In particular, the invention is directed at obtaining metabolic mutants in a simple, direct and specific manner. In a preferred embodiment it is also possible to obtain desired mutants not comprising recombinant DNA, thereby facilitating incorporation thereof in products for human consumption or application, due to shorter legislative procedures. The method according to the invention involves random mutation and specific selection of the desired metabolic mutant. Knockout, mutants wherein a gene associated with metabolism is absent or inactivated and mutants with increased or decreased DNA binding capacity are also claimed.
Type:
Grant
Filed:
April 22, 2003
Date of Patent:
June 11, 2013
Assignee:
DuPont Nutrition Biosciences ApS
Inventors:
Leendert Hendrik De Graaff, Henriëtta Catharina Van Den Broeck, Jacob Visser
Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.
Type:
Grant
Filed:
April 8, 2008
Date of Patent:
May 21, 2013
Assignee:
University of Florida Research Foundation, Inc.
Inventors:
Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
Abstract: The present invention provides the genome sequence of Pichia pastoris and manually curated annotation of protein-coding genes. The invention provides novel nucleic acids, proteins, and related expression vectors useful for genetic engineering of methylotrophic yeast strains, as well as engineered methylotrophic yeast strains particularly Pichia pastsoris, and use thereof for recombinant production of heterologous proteins including glycoproteins suitable for use in mammals including humans.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
May 14, 2013
Assignees:
VIB, VZW, Universiteit Gent, Research Corporation Technologies, Inc.
Inventors:
Nico Callewaert, Kristof De Schutter, Petra Tiels, Yao-Cheng Lin
Abstract: The present invention provides a collagen accumulation inhibitor, a collagen accumulation-inhibiting method, a method for searching for a substance which regulates the type-I collagen gene transcription regulating ability and the like, said matters being useful in a medical field for a prophylaxis or the treatment of a disease caused by an excessive accumulation for a collagen (for example fibrosis).
Abstract: A method for promoting and suppressing auto-induction of transcription of a cloned gene 1 of bacteriophage T7 in cultures of bacterial cells grown batchwise is disclosed. The transcription is under the control of a promoter whose activity can be induced by an exogenous inducer whose ability to induce said promoter is dependent on the metabolic state of said bacterial cells.
Abstract: The present invention provides a method for constructing recombinant translationally coupled operons, a method for producing useful metabolites using the bacterium containing the coupled operons, and a method for monitoring gene expression.
Type:
Grant
Filed:
February 19, 2009
Date of Patent:
March 12, 2013
Assignee:
Ajinomoto Co., Inc.
Inventors:
Andrey Yurievich Gulevich, Aleksandra Yurievna Skorokhodova, Vladimir Yurievich Ermishev, Natalya Igorevna Minaeva, Danila Vadimovich Zimenkov, Aleksandr Aleksandrovich Krylov, Irina Vladimirovna Biryukova, Sergei Vladimirovich Mashko